Amgen has secured a landmark US approval for the first ever biosimilar of AbbVie’s Humira, the $14 billion a year blockbuster which is the world’s bestselling medicine. The news came on Friday ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

However, according to Samsung Bioepis, ABBV continues to claim 72% of the adalimumab market in the U.S. as of November, even as its biosimilar threat has gained ground, claiming 23% of the market ...